MIRA INFORM REPORT

Report No. :	505651
Report Date :	26.04.2018

IDENTIFICATION DETAILS

Name :	WENZHOU LONGWAN MEDICAL DEVICE FACTORY
Registered Office :	West of 2/F, No. 6 Building, No. 217 Linghua Road, Oujiangkou Industrial Agglomeration Area, Wenzhou, Zhejiang Province
Country :	China
Financials (as on) :	31.12.2017
Date of Incorporation :	04.10.1986
Com. Reg. No.:	913303011452269321
Legal Form :	Shares Jointly Owned Enterprise
Line of Business :	· Manufacturing and selling of II items of medical apparatus and instruments, and hardware; manufacturing and processing thermoplastics welding equipment; importing and exporting commodities and technology. Subject is mainly engaged in manufacturing and selling medical apparatus and instruments.
No. of Employees :	50

RATING & COMMENTS

(Mira Inform has adopted New Rating mechanism w.e.f. 23^rd January 2017)

MIRA’s Rating :

A

Credit Rating	Explanation	Rating Comments
A	Acceptable Risk	Business dealings permissible with moderate risk of default

Status :	Satisfactory
Payment Behaviour :	Slow but Correct
Litigation :	Clear

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List

Country Name	Previous Rating (30.09.2017)	Current Rating (31.12.2017)
China	A2	A2

Risk Category	ECGC Classification
Insignificant	A1
Low Risk	A2
Moderately Low Risk	B1
Moderate Risk	B2
Moderately High Risk	C1
High Risk	C2
Very High Risk	D

CHINA - ECONOMIC OVERVIEW

Since the late 1970s, China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role. China has implemented reforms in a gradualist fashion, resulting in efficiency gains that have contributed to a more than tenfold increase in GDP since 1978. Reforms began with the phaseout of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, growth of the private sector, development of stock markets and a modern banking system, and opening to foreign trade and investment. China continues to pursue an industrial policy, state support of key sectors, and a restrictive investment regime. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2016 stood as the largest economy in the world, surpassing the US in 2014 for the first time in modern history. China became the world's largest exporter in 2010, and the largest trading nation in 2013. Still, China's per capita income is below the world average.

After keeping its currency tightly linked to the US dollar for years, China in July 2005 moved to an exchange rate system that references a basket of currencies. From mid-2005 to late 2008, the renminbi appreciated more than 20% against the US dollar, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing announced it would allow a resumption of gradual liberalization. From 2013 until early 2015, the renminbi (RMB) appreciated roughly 2% against the dollar, but the exchange rate fell 13% from mid-2015 until end-2016 amid strong capital outflows in part stemming from the August 2015 official devaluation; in 2017 the RMB resumed appreciating against the dollar – roughly 7% from end-of-2016 to end-of-2017. From 2013 to 2017, China had one of the fastest growing economies in the world, averaging slightly more than 7% real growth per year. In 2015, the People’s Bank of China announced it would continue to carefully push for full convertibility of the renminbi, after the currency was accepted as part of the IMF’s special drawing rights basket. However, since late 2015 the Chinese Government has strengthened capital controls and oversight of overseas investments to better manage the exchange rate and maintain financial stability.

The Chinese Government faces numerous economic challenges including: (a) reducing its high domestic savings rate and correspondingly low domestic household consumption; (b) managing its high corporate debt burden to maintain financial stability; (c) controlling off-balance sheet local government debt used to finance infrastructure stimulus; (d) facilitating higher-wage job opportunities for the aspiring middle class, including rural migrants and college graduates, while maintaining competitiveness; (e) dampening speculative investment in the real estate sector without sharply slowing the economy; (f) reducing industrial overcapacity; and (g) raising productivity growth rates through the more efficient allocation of capital and state-support for innovation. Economic development has progressed further in coastal provinces than in the interior, and by 2016 more than 169.3 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of China’s population control policy known as the “one-child policy” - which was relaxed in 2016 to permit all families to have two children - is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and urbanization. The Chinese Government is seeking to add energy production capacity from sources other than coal and oil, focusing on natural gas, nuclear, and clean energy development. In 2016, China ratified the Paris Agreement, a multilateral agreement to combat climate change, and committed to peak its carbon dioxide emissions between 2025 and 2030.

The government's 13th Five-Year Plan, unveiled in March 2016, emphasizes the need to increase innovation and boost domestic consumption to make the economy less dependent on government investment, exports, and heavy industry. However, China has made more progress on subsidizing innovation than rebalancing the economy. Beijing has committed to giving the market a more decisive role in allocating resources, but the Chinese Government’s policies continue to favor state-owned enterprises and emphasize stability. Chinese leaders in 2010 pledged to double China’s GDP by 2020, and the 13th Five Year Plan includes annual economic growth targets of at least 6.5% through 2020 to achieve that goal. In recent years, China has renewed its support for state-owned enterprises in sectors considered important to "economic security," explicitly looking to foster globally competitive industries. Chinese leaders also have undermined some market-oriented reforms by reaffirming the “dominant” role of the state in the economy, a stance that threatens to discourage private initiative and make the economy less efficient over time. The slight acceleration in economic growth in 2017—the first such uptick since 2010—gives Beijing more latitude to pursue its economic reforms, focusing on financial sector deleveraging and its Supply-Side Structural Reform agenda, first announced in late 2015.

Source : CIA

COMPANY NAME AND ADDRESS

COMPANY NAME	Wenzhou Longwan Medical Device Factory
CURRENT ADDRESS	No. 8 Jinjiang Road, Wenzhou Industry Area, Zhejiang Province 325013 PR China
REGISTERED ADDRESS	West of 2/F, No. 6 Building, No. 217 Linghua Road, Oujiangkou Industrial Agglomeration Area, Wenzhou, Zhejiang Province
TEL. NO.	86 (0) 577-86651568
FAX NO.	N/a

EXECUTIVE SUMMARY

Date of Registration : october 4, 1986

Unified social credit code : 913303011452269321

LEGAL FORM : Shares jointly owned enterprise

CHIEF EXECUTIVE : zeng zhiyao (LEGAL REPRESENTATIVE)

REGISTERED CAPITAL : CNY 580,000

staff : 50

BUSINESS CATEGORY : manufacturing & TRADING

Revenue : CNY 5,280,000 (AS OF DEC. 31, 2017)

EQUITIES : CNY 1,230,000 (AS OF DEC. 31, 2017)

WEBSITE : www.taiyumed.com

E-MAIL : info@taiyumed.com

PAYMENT : SLOW BUT CORRECT

MARKET CONDITION : fair

FINANCIAL CONDITION : fairly stable

OPERATIONAL TREND : ordinary

GENERAL REPUTATION : average

Adopted abbreviations (as follows)

SC - Subject Company (the company inquired by you)

N/A – Not available

CNY – China Yuan Ren Min Bi

OPERATIONAL TREND & GENERAL REPUTATION

This section aims at indicating the relative positions of SC in respect of its operational trend & general reputation

Operational Trend:- General Reputation:-

Upward Excellent

Steady Good

Fairly Steady Fairly Good

Ordinary Average

Fair Fair

Stagnant Detrimental

Downward Not known

Not known Not yet be determined

Not yet be determined

LEGAL STATUS & HISTORY

SC was established as shares jointly owned enterprise of PRC with State Administration of Industry & Commerce (SAIC) under Unified Social Credit Code: 913303011452269321.

SC’s Import and Export Enterprise Code: 3300145226932

SC’s registered capital: CNY 580,000

SC’s paid-in capital: CNY 580,000

Registration Change Record:-

Date	Change of Contents	Before the change	After the change
1989-9-22	Registered Capital	CNY 26,000	CNY 48,800
2006-5-18	Registered Capital	CNY 48,800	CNY 580,000
2017-9-1	Registration No./ Unified Social Credit Code	330303000038004	913303011452269321

Current Co search indicates SC’s shareholders & chief executives are as follows:-

Name of Shareholder (s)	% of Shareholding
Zeng Zhiyao	60
Zhu Chunliu	40

SC’s Chief Executives:-

Position	Name
Legal Representative, Chairman and General Manager	Zeng Zhiyao

RECENT DEVELOPMENT

No recent development was found during our checks at present.

SHAREHOLDER CHART & BACKGROUND

Name % of Shareholding

Zeng Zhiyao 60

Zhu Chunliu 40

MANAGEMENT

Zeng Zhiyao, Legal Representative, Chairman and General Manager

-----------------------------------------------------------------------------------------------------

Ø Gender: M

Ø Nationality: China

Ø Qualification: University

Ø Working experience (s):

At present, working in SC as legal representative, chairman and general manager

BUSINESS OPERATION

SC’s registered business scope includes manufacturing and selling II items of medical apparatus and instruments, and hardware; manufacturing and processing thermoplastics welding equipment; importing and exporting commodities and technology.

SC is mainly engaged in manufacturing and selling medical apparatus and instruments.

SC’s products mainly include:

Aneroid sphygmomanometer

Palm sphygmomanometer

Stethoscope

Parts

Etc.

SC sources its materials 100% from domestic market. SC sells 80% of its products in domestic market, and 20% to overseas market.

The buying terms of SC include Check, T/T and Credit of 30-60 days. The payment terms of SC include T/T, L/C and Credit of 30-60 days.

Staff & Office:

--------------------------

SC is known to have approx. 50 staff at present.

SC rents an area as its operating office and factory, but the detailed information is unknown.

RELATED COMPANY

SC is not known to have any subsidiary at present.

PAYMENT

Overall payment appraisal:

( ) Excellent ( ) Good (X) Average ( ) Fair ( ) Poor ( ) Not yet be determined

The appraisal serves as a reference to reveal SC's payments habits and ability to pay. It is based on the 3 weighed factors: Trade payment experience (through current enquiry with SC's suppliers), our delinquent payment and our debt collection record concerning SC.

Trade payment experience: SC did not provide any name of trade/service suppliers and we have no other sources to conduct the enquiry at present.

Delinquent payment record: None in our database.

Debt collection record: No overdue amount owed by SC was placed to us for collection within the last 6 years.

BANKING

Basic Bank:

Longwan Rural Commercial Bank Bailouxia Office

AC#: 201000018704410

FINANCIALS

Financial Summary

Unit: CNY’000	As of Dec. 31, 2017
Total assets	7,060
	-------------
Total liabilities	5,830
Equities	1,230
	-------------
Revenue	5,280
Profits	110

Important Ratios

=============

	As of Dec. 31, 2017
*Liabilities to assets	0.83
*Net profit margin (%)	2.08
*Return on total assets (%)	1.56
*Revenue / Total assets	0.75

FINANCIAL COMMENTS

PROFITABILITY: AVERAGE

l The revenue of SC appears fair in its line.

l SC’s net profit margin is average.

l SC’s return on total assets is average.

LIQUIDITY: FAIR

l SC’s revenue is in a fair level, comparing with the size of its total assets.

LEVERAGE: AVERAGE

l The debt ratio of SC is average.

l The risk for SC to go bankrupt is above average.

Overall financial condition of the SC: Fairly Stable.

CONCLUSIONS

SC is considered small-sized in its line with fairly stable financial conditions.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	INR 66.70
UK Pound	1	INR 93.14
Euro	1	INR 81.43
CNY	1	INR 10.56

Note: Above are approximate rates obtained from sources believed to be correct

INFORMATION DETAILS

Analysis Done by :	NIS
Report Prepared by :	NIT

RATING EXPLANATIONS

Credit Rating	Explanation	Rating Comments
A++	Minimum Risk	Business dealings permissible with minimum risk of default
A+	Low Risk	Business dealings permissible with low risk of default
A	Acceptable Risk	Business dealings permissible with moderate risk of default
B	Medium Risk	Business dealings permissible on a regular monitoring basis
C	Medium High Risk	Business dealings permissible preferably on secured basis
D	High Risk	Business dealing not recommended or on secured terms only
NB	New Business	No recommendation can be done due to business in infancy stage
NT	No Trace	No recommendation can be done as the business is not traceable

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

· Financial condition covering various ratios

· Company background and operations size

· Promoters / Management background

· Payment record

· Litigation against the subject

· Industry scenario / competitor analysis

· Supplier / Customer / Banker review (wherever available)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.